Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. 
Introduction
Most anti-cancer therapies cannot discriminate between malignant and normal tissues, since their action depends on the increased proliferation rate of tumor versus benign cells. 1 Furthermore, high systemic doses of cytotoxic/cytostatic drugs are generally required to achieve therapeutically active concentrations within the tumor, thus frequently resulting in severe adverse effects. The approach of antibodybased therapies to selectively target therapeutically active molecules to tumor tissues is highly promising. Few of such immunotherapy agents are currently in clinical development or have been approved for treating solid cancers or hematologic malignancies (Mylotarg, EMD273063). 2, 3 The basic prerequisite to apply this strategy is tumor-selective expression of the specific target structure. The extra-domain B of fibronectin (ED-B FN) has been suggested as a potential target for novel anti-cancer therapies in patients with solid tumors. 4 Fibronectin (FN) is a ubiquitously expressed high-molecular weight extracellular matrix glycoprotein which exists in various isoforms. 5, 6 Sequence analysis has revealed that FN consists of three different sequence homologies designated as type I, II, and III repeats, respectively. 7 Three sites of alternative splicing within the type III repeats of the FN molecule have so far been identified: ED-A (type III homology extra domain A), ED-B (type III homology extra domain B), and IIICS (type III homology connecting segment). 8 Since the ED-B domain is preferentially expressed by transformed cells in vitro, 9 ED-B FN was designated as oncofetal or embryonic FN, reflecting its expression mainly in fetal tissues and solid tumors. 10, 11 ED-B FN is synthesized, secreted and deposited to the extracellular matrix structures by numerous cell types such as endothelial cells of newly formed blood vessels, myofibroblasts and, most notably, expression is tightly controlled and appears to be restricted to embryonic tissues, a few normal adult organs and wound healing. 10, 11, 19 However, the functional significance of ED-B-FN is still to be established. In vitro studies have yielded contradictory results, and studies with in vivo models on single deletion of EIIIA or EIIIB have failed to provide significant insight into the possible functions of these splice variants. In fact, EIIIA-null or EIIIB-null mice are viable, fertile, and maintain normal physiological angiogenesis after birth. 20, 21 Nevertheless, EIIIA/EIIIB doublenull embryos display multiple cardiovascular defects, thus indicating a crucial involvement in angiogenesis and in cardiovascular development of the EIIIA and EIIIB-containing splice variants of FN. 22 While physiologic expression of ED-B FN is rare in healthy adults, it can occur in chronic pathological conditions associated with new blood vessel formation 23, 24 such as ocular-retinal diseases, 25, 26 severe atherosclerosis, 27 and inflammatory rheumatoid disease. 28 ED-B FN is abundant in tissues of almost all human solid cancers, irrespective of histotype. 4 Since ED-B FN expression has been more extensively evaluated in solid cancers, we thought it worthwhile to explore this biologic event also in a broad range of hematologic malignancies and normal lymphoid and hematopoietic tissues. 
Materials and Methods

Specimens
Paraffin-embedded and shock-frozen specimen of hematopoietic malignancies were drawn from the files of the Institute of Pathology, Campus Benjamin Franklin, Charité, Berlin, Germany (Table 1) . Additionally, 3 lymph node biopsies with the diagnosis of EBV-associated lymphoproliferation, 13 tonsils with follicular hyperplasia, 10 tumor-free lymph nodes harvested from the drainage of carcinomas, 12 enlarged lymph nodes with severe inflammation, and 9 bone marrow biopsies with non-neoplastic alterations were included in the study (Table 2) . Finally, frozen specimens of 2 CLL, 6 mantle cell, and 3 follicular lymphomas were analyzed. The hematopoietic tumors were classified according to WHO classification. 29 Paraffinembedded and frozen specimens of 6 cases of clear cell renal cell carcinoma were included as positive controls.
The mouse embryonal teratocarcinoma cell line F9 was purchased from ATCC (Manassas, Virginia, USA 
Statistical analyses
Statistical analyses were performed with the U/H-ranking tests using 13.0 Base System SPSS for Windows (SPSS GmbH Software, Munich, Germany).
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RESULTS
Reliability and localization of ED-B FN detection in paraffin-embedded specimens
This study presents the first systematic data about the detection of the ED-B epitope of FN in paraffin-embedded tissues. To verify the expression pattern of ED-B FN in paraffin-embedded tissues, we used the mAb MX1 and the fusion protein L19IL2.
Both anti-ED-B FN constructs detected the same ED-B FN expression pattern in paraffin-embedded and frozen specimens of renal carcinoma (n=6), lymphocytic lymphoma (CLL; n=2), mantle cell lymphoma (n=6), and follicular lymphoma (n=3).
Identical ED-B FN expression patterns were also found in the paraffin-embedded half and the frozen half of the split F9 tumor specimens ( classical Hodgkin lymphoma (mixed cellularity and nodular sclerosis) revealed that ED-B FN is mostly co-localized with blood vessels, which were identified by their CD34-positive endothelia (Fig. 3) . By investigating 1 normal lymph node, 1 lymph node with lymphadenopathy, 1 hyperplastic tonsil, and 2 normal bone marrow samples we also confirmed that the mostly small ED-B FN deposits are localized perivascular in non-malignant lymphoid and hematopoietic tissues.
ED-B FN expression in normal and hyperplastic lymphoid tissue and normal bone marrow
Blood vessels of normal lymphoid tissue rarely and weakly express ED-B FN (Fig 4) .
ED-B FN expression in hyperplastic tonsils was heterogeneous. More than 90% of all blood vessels were ED-B FN-positive in 7/13 tonsils, whereas 5/13 tonsils show very low perivascular ED-B FN expression ( Table 2 
ED-B FN expression in nodal and extranodal lymphomas
Nodal and extranodal lymphomas showed significantly more ED-B FN-positive blood vessels than normal lymphoid tissues (p<0.001; Table 1 ). This finding was true for For
Discussion
The identification of suitable targets for more selective and less toxic therapies for advanced malignant neoplasias is crucial for the success of innovative treatment approaches. Consequently, great emphasis has been put on the identification of unique molecular pathways or specific cellular antigens of malignant cells. Selective treatments interacting with some of these tumor cell-associated targets were found to be highly beneficial, including the monoclonal antibodies rituximab in combination with chemotherapy for B cell lymphoma, 36 and trastuzumab for Her2/neu overexpressing breast cancer. 37 The extra domain B of fibronectin (ED-B FN) represents such a stromal tumor tissue target. 9 Further validating this concept, the ED-B FN targeting antibody L19 acting as a vehicle for tissue factor or TNFα (tumor necrosis factor α) to the tumor vasculature, was found to induce tumor necrosis. 44, 45 ED-B FN expression was found to a variable extent and with different expression patterns by immunohistochemistry on cryostat tissue sections in almost all solid cancers studied thus far. 4 To extend these studies to a reliable sample of hematologic malignancies and to include decalcified bone marrow biopsies, we Wagner et al. 47 and Blum et al. 48 I-L19SIP to lymphoma lesions was not only selective and long-lasting (up to 12 days after injection), but also surprisingly high with an absorbed dose to the target lesion of approximately 14-22.7 Gy, sparing radiosensitive organs such as red bone marrow and the kidneys. Furthermore, the two HL patients experienced a sustained partial remission according to RECIST, which was associated with clinical benefit, lasting for at least 2 and 3 months, respectively. In contrast, the SLL-NHL patient had only short disease stabilization and did not benefit from treatment.
In conclusion, developing an antigen-retrieval method for immunohistochemistry on paraffin sections we were able to demonstrate ED-B FN depositions in the 
